In 2011, new treatment recommendations for juvenile idiopathic arthritis (JIA) were proposed, inroads were made towards understanding the heterogeneity of this disease, and data were presented demonstrating the potential efficacy of DMARD combination therapies for JIA treatment. These advances hold promise for improved management of JIA in 2012 and beyond.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Petty, R. E. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31, 390–392 (2004).
Martini, A. Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis? J. Rheumatol. 30, 1900–1903 (2003).
Ravelli, A. et al. Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum. 63, 267–275 (2011).
Barnes, M. G. et al. Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis. Arthritis Rheum. 62, 3249–3258 (2010).
Hirschfeld, S. & Saint-Raymond, A. Pediatric regulatory initiatives. Handb. Exp. Pharmacol. 205, 245–268 (2011).
Beukelman, T. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hoboken) 63, 465–482 (2011).
Hashkes, P. J. Pediatric rheumatology: strengths and challenges of a new guide for treating JIA. Nat. Rev. Rheumatol. 7, 377–378 (2011).
Sawhney, S. & Magalhães, C. S. Paediatric rheumatology—a global perspective. Best Pract. Res. Clin. Rheumatol. 20, 201–221 (2006).
Ma, M. H., Kingsley, G. H. & Scott, D. L. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford) 49, 91–98 (2010).
Tynjälä, P. et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann. Rheum. Dis. 70, 1605–1612 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Martini, A. New takes on categorization and treatment. Nat Rev Rheumatol 8, 67–68 (2012). https://doi.org/10.1038/nrrheum.2011.198
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2011.198
This article is cited by
-
MicroRNA-125b regulates Th17/Treg cell differentiation and is associated with juvenile idiopathic arthritis
World Journal of Pediatrics (2020)
-
Management of juvenile idiopathic arthritis: hitting the target
Nature Reviews Rheumatology (2015)
-
Fatigue in children with juvenile idiopathic arthritis: reliability of the “Pediatric Quality of Life Inventory-Multidimensional Fatigue Scale”
Rheumatology International (2015)